Nikolaos C.George Ph.D. (Nick)

Partner

纽约 + 1.212.326.3887

Nick George has more than 30 years of experience developing and evaluating biologics-based patent portfolios. He has devised worldwide patent prosecution strategies involving such diverse technologies as therapeutic antibodies, antibody drug conjugates, cellular therapeutics (including stem cell, natural killer cell, macrophage, regulatory cell, chimeric antigen receptor, and induced pluripotent stem cell [iPSC] therapeutics), gene therapies, oncolytic viruses, gene editing, antisense and mRNA therapeutics, peptide therapeutics, diagnostics, and enzyme replacements, among others.

Nick has developed patent strategies for such marketed products as Fuzeon®, Kynamro®, Fabrazyme®, Syvek®, and Talymed® and for clinical and pre-clinical candidates of such companies as BioMarin Pharmaceutical, BMS/Celgene, Celldex Therapeutics, Coya Therapeutics, and Turnstone Biologics. He also has developed patent strategies for such diagnostic products as Phenosense, GeneSeq, Replication Capacity, and the companion diagnostic, Trofile.

Nick also routinely provides advice on freedom-to-operate, noninfringement, invalidity, and patentability matters and conducts due diligence on behalf of investment firms and life sciences companies.

Nick holds a Ph.D. in genetics from the University of California, Berkeley (1990). Following a postdoctoral fellowship at Columbia University, he joined the legal intern program at his previous firm, during which time he also attended the evening program of Fordham University School of Law.

经验

  • Coya Therapeutics announces its initial public offeringJones Day represented Coya Therapeutics Inc. as IP counsel in connection with its December 2022 initial public offering.
  • Celldex Therapeutics develops worldwide patent portfolios for anti-tyrosine kinase receptor therapeutic antibodiesJones Day is representing Celldex Therapeutics, Inc. in connection with the development and prosecution of global portfolios related to the company's lead clinical and pre-clinical anti-tyrosine kinase receptor therapeutic antibodies.
  • Turnstone Biologics develops patent portfolios for its oncolytic virus clinical candidateJones Day is representing Turnstone Biologics Corp. in the development of patent portfolios covering its oncolytic virus programs, including its current clinical candidate.
  • ToolGen faces off in two patent interferences involving CRISPR/Cas9 applicationJones Day is representing ToolGen, Inc. in two patent interferences involving CRISPR/Cas9 technology.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • ToolGen seeks patent protection for CRISPR technologyJones Day is prosecuting patent applications and developing a patent portfolio on behalf of ToolGen, Inc. for CRISPR technology.
  • RaNA Therapeutics (now known as Translate Bio) acquires Shire's messenger RNA therapy platformJones Day acted as IP counsel to RaNA Therapeutics, Inc. (now known as Translate Bio) in connection with its acquisition of Shire Pharmaceuticals' messenger RNA therapy platform (MRT), with lead programs in cystic fibrosis and urea cycle disorders.
  • Celgene develops worldwide patent portfolios covering CAR-T and other cellular therapeuticsJones Day is advising Celgene Corporation in the strategic development of worldwide patent portfolios covering CAR-T and other cellular therapeutics.
  • Celgene develops patent portfolio for anti-CD47 therapeutic antibodiesJones Day represented Celgene Corporation in the development of a portfolio of patents directed to anti-CD47 therapeutic antibodies.
  • Genzyme (Sanofi) develops patent portfolio for antisense drug Kynamro®Jones Day represented Genzyme Corporation (Sanofi) in developing patent portfolios related to the apolipoprotein B-targeting antisense drug, Kynamro® (mipomersen), which was the first antisense drug to reach the market and used for the treatment of homozygous familial hypercholesterolemia.
  • Celgene enters strategic collaboration with MedImmune for hematologic malignanciesJones Day acted as special patent counsel, IP technology transaction counsel, and tax counsel on Celgene Corporation's strategic collaboration with MedImmune regarding human monoclonal antibody MEDI-4736 directed to PD-L1 to allow the immune system to continue to fight blood cancers.
  • Kirin Pharma Kabushiki Kaisha establishes patent portfolio for human LIGHT antibodiesJones Day represented Kirin Pharma Kabushiki Kaisha and Kirin Pharma USA, Inc. in the development of its patent portfolio and prosecution strategies related to human LIGHT antibodies.
  • PDL BioPharma goes head to head against UCB Pharma in patent interference involving reshaped humanized immunoglobulinsJones Day represented PDL BioPharma, Inc. in patent interference against UCB Pharma S.A. involving "reshaped" humanized immunoglobulins.
  • 演讲

    • October 19, 2022
      East-West Biopharma Summit Road Trip, New York City, October 19, 2022